Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 201–300 of 1,026

1. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention
   T WHITESIDE · 2005 · Seminars in Cancer Biology
2. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
   Qingzhu Jia, Wei Wu, Yuqi Wang, Peter B. Alexander, Chengdu Sun, Zhihua Gong, Jia-Nan Cheng, Huaibo Sun, Yanfang Guan, Xuefeng Xia et al. · 2018 · Nature Communications
3. PD-L1 Expression in Lung Cancer
   Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
4. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
   Haidong Tang, Yang Wang, Lukasz K. Chlewicki, Yuan Zhang, Jingya Guo, Wei Ping Liang, Jieyi Wang, Xiaoxiao Wang, Yang‐Xin Fu · 2016 · Cancer Cell
5. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
   Nakanishi, Juro, Wada, Yoshihiro, Matsumoto, Koichiro, Azuma, Miyuki, Kikuchi, Ken, Ueda, Shoichi · 2007 · Cancer Immunology, Immunotherapy
6. Oral Mucosal Epithelial Cells
   Groeger, Sabine, Meyle, Joerg · 2019 · Frontiers in Immunology
7. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
   Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe et al. · 2015 · Blood
8. Resistance Mechanisms to Anti-PD Cancer Immunotherapy
   Vesely, Matthew D., Zhang, Tianxiang, Chen, Lieping · 2022 · Annual Review of Immunology
9. PD‐1 and PD‐L1 upregulation promotes CD8 + T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
   Feng Shi, Ming Shi, Zhen Zeng, Ruizhao Qi, Zhen‐Wen Liu, Ji‐Yuan Zhang, Yongping Yang, Po Tien, Fu‐Sheng Wang · 2010 · International Journal of Cancer
10. Mechanisms regulating PD-L1 expression on tumor and immune cells
    Shuming Chen, George Austin Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping Yen Wei, Drew M. Pardoll, Fan Pan, Suzanne Louise Topalian · 2019 · Journal for ImmunoTherapy of Cancer
11. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
    Chen, Limo, Diao, Lixia, Yang, Yongbin, Yi, Xiaohui, Rodriguez, B. Leticia, Li, Yanli, Villalobos, Pamela A., Cascone, Tina, Liu, Xi, Tan, Lin et al. · 2018 · Cancer Discovery
12. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
    Winograd, Rafael, Byrne, Katelyn T., Evans, Rebecca A., Odorizzi, Pamela M., Meyer, Anders R.L., Bajor, David L., Clendenin, Cynthia, Stanger, Ben Z., Furth, Emma E., Wherry, E. John et al. · 2015 · Cancer Immunology Research
13. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Marcella Callea, Laurence K. Albiges, Mamta Gupta, Su–Chun Cheng, Elizabeth M. Genega, André Poisl Fay, Jiaxi Song, Ingrid Carvo, Rupal Satish Bhatt, Michael B. Atkins et al. · 2015 · Cancer Immunology Research
14. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
    Orin G. Bloch, Courtney A. Crane, Rajwant Kaur, Michael Safaee, Martin J. Rutkowski, Andrew T. Parsa · 2013 · Clinical Cancer Research
15. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
    Aaron Michael Goodman, Sandip Pravin Patel, Razelle Kurzrock · 2016 · Nature Reviews Clinical Oncology
16. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    Woods, David M., Sodré, Andressa L., Villagra, Alejandro, Sarnaik, Amod, Sotomayor, Eduardo M., Weber, Jeffrey · 2015 · Cancer Immunology Research
17. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
    Young Kwang Chae, Ayush Arya, Wade Thomas Iams, Marcelo Rocha de Souza Cruz, Sunandana Chandra, Jaehyuk Choi, Francis Joseph Giles · 2018 · Journal for ImmunoTherapy of Cancer
18. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Luisa Carbognin, Sara Pilotto, Michèle Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi et al. · 2015 · PLoS ONE
19. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR‐23a‐3p and Up‐regulate Programmed Death Ligand 1 Expression in Macrophages
    Liu, Jiatao, Fan, Lulu, Yu, Hanqing, Zhang, Ju, He, Yong, Feng, Dechun, Wang, Fang, Li, Xiaoqiu, Liu, Qingqing, Li, Yuhuan et al. · 2019 · Hepatology
20. Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)
    Seung Jin Lee, Byeong‐Churl Jang, Soo-Woong Lee, Young‐Il Yang, Seong‐Il Suh, Yeong-Min Park, Sangtaek Oh, Jae‐Gook Shin, Sheng Yao, Lieping Chen et al. · 2006 · FEBS Letters
21. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death
    Di Huang, Jianing Chen, Linbin Yang, Qian Ouyang, Jiaqian Li, Liyan Lao, Jinghua Zhao, Jiang Liu, Yiwen Lu, Yue Xing et al. · 2018 · Nature Immunology
22. A critical role for the programmed death ligand 1 in fetomaternal tolerance
    Indira Guleria, Arezou Khosroshahi, Mohammed Javeed Ansari, Antje Habicht, Miyuki Azuma, Hideo Yagita∥, Randolph J. Noelle, Anthony J. Coyle, Andrew L. Mellor, Samia Joseph Khoury et al. · 2005 · The Journal of Experimental Medicine
23. PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: Associations with localized stage progression
    Inman, Brant A., Sebo, Thomas J., Frigola, Xavier, Dong, Haidong, Bergstralh, Eric J., Frank, Igor, Fradet, Yves, Lacombe, Louis, Kwon, Eugene D. · 2007 · Cancer
24. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
    Julien Caldéraro, Benoı̂t Rousseau, Giuliana Amaddeo, Marion Mercey-Ressejac, Cécile Charpy, Charlotte E. Costentin, Alain Luciani, Elie‐Serge Zafrani, Alexis Laurent, Daniel Azoulay et al. · 2016 · Hepatology
25. Immune resistance orchestrated by the tumor microenvironment
    Gajewski, Thomas F., Meng, Yuru, Blank, Christian, Brown, Ian, Kacha, Aalok, Kline, Justin, Harlin, Helena · 2006 · Immunological Reviews
26. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
    Jung-Mao Hsu, Weiya Xia, Yi-Hsin Hsu, Li-Chuan Chan, Wen-Hsuan Yu, Jong‐Ho Cha, Chun‐Te Chen, Hsin-Wei Liao, Chu‐Wei Kuo, Kay‐Hooi Khoo et al. · 2018 · Nature Communications
27. Recent progress in multidisciplinary treatment for patients with esophageal cancer
    Masayuki Watanabe, Reiko Otake, Ryotaro Kozuki, Tasuku Toihata, Keita Takahashi, Akihiko Okamura, Yu Imamura · 2019 · Surgery Today
28. B lymphocytes and cancer: a love-hate relationship
    Yuen, Grace J., Demissie, Ezana, Pillai, Shiv · 2016 · Trends in cancer
29. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
30. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
    David F. McDermott, Charles G. Drake, Mario Sznol, Toni K. Choueiri, John D. Powderly, David Carl Smith, Julie Renee Brahmer, Richard D. Carvajal, Hans J. Hammers, Igor J. Puzanov et al. · 2015 · Journal of Clinical Oncology
31. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, Jibiao Wu, Zhen Zhang · 2021 · Frontiers in Pharmacology
32. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
    Thomas F. Gajewski, Seng‐Ryong Woo, Yuanyuan Zha, Robbert M. Spaapen, Yan Zheng, Leticia P. Corrales, Stefani Spranger · 2013 · Current Opinion in Immunology
33. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
    Zhu, Ying, Yang, Jing, Xu, Da, Gao, Xiao-Mei, Zhang, Ze, Hsu, Jennifer L, Li, Chia-Wei, Lim, Seung-Oe, Sheng, Yuan-Yuan, Zhang, Yu et al. · 2019 · Gut
34. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer
35. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
    Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu · 2019 · Frontiers in Immunology
36. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
    Guoying Zhou, Dave Sprengers, Patrick P.C. Boor, Michail Doukas, Hannah M. Schutz, Shanta Mancham, Alexander Pedroza‐González, Wojciech Grzegorz Polak, Jeroen de Jonge, Marcia Patricia Gaspersz et al. · 2017 · Gastroenterology
37. Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
    Xuewu Zhang, Jean-Claude D. Schwartz, Xiaoling Guo, Sumeena Bhatia, Erhu Cao, Lieping Chen, Zhong‐Yin Zhang, Michael A. Edidin, Stanley G. Nathenson, Steven C. Almo · 2004 · Immunity
38. The role of microglia in central nervous system immunity and glioma immunology
    Yang, Isaac, Han, Seunggu J., Kaur, Gurvinder, Crane, Courtney, Parsa, Andrew T. · 2010 · Journal of Clinical Neuroscience
39. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
    Rony Dahan, Emanuela I. Sega, John Engelhardt, Mark Selby, Alan J. Korman, Jeffrey V. Ravetch · 2015 · Cancer Cell
40. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
    Long Zhang, Thomas Frank Gajewski, Justin Paul Kline · 2009 · Blood
41. Current insights into the regulation of programmed cell death by NF-κB
    Jui Dutta, Y Fan, N Gupta, Gaofeng Fan, Céline Gélinas · 2006 · Oncogene
42. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    Jiabei He, Ying Hu, Mingming Hu, Baolan Li · 2015 · Scientific Reports
43. Effects of exosomes on pre-metastatic niche formation in tumors
    Yaxin Guo, Xiang Ji, Jinbo Liu, Dandan Fan, Quanbo Zhou, Chen Chen, Weiwei Wang, Guixian Wang, Haijiang Wang, Weitang Yuan et al. · 2019 · Molecular Cancer
44. Signal pathways of melanoma and targeted therapy
    Weinan Guo, Huina Wang, Chunying Li · 2021 · Signal Transduction and Targeted Therapy
45. B7x: A widely expressed B7 family member that inhibits T cell activation
    Xingxing Zang, P’ng Loke, Jayon Kim, KENNETH M. M. MURPHY, Rebecca Waitz, James Patrick Allison · 2003 · Proceedings of the National Academy of Sciences
46. Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
    Haonan Chang, Bei‐Yuan Liu, Yun‐Kun Qi, Yang Zhou, Yanping Chen, Kai‐Mai Pan, Wenwen Li, Xiuman Zhou, Weiwei Ma, Caiyun Fu et al. · 2015 · Angewandte Chemie International Edition
47. Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
    Gordon James Freeman, E. John Wherry, Rafi Ahmed, Arlene H. Sharpe · 2006 · The Journal of Experimental Medicine
48. PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
    Ryō Yamamoto, Momoko Nishikori, Toshio Kitawaki, Tomomi Sakai, Masakatsu Hishizawa, Masaharu Tashima, Tadakazu Kondo, Katsuyuki Ohmori, Masayuki Kurata, Takamasa Hayashi et al. · 2008 · Blood
49. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
    Kevin C. Soares, Agnieszka A. Rucki, Annie A. Wu, Kelly L. Olino, Qian Xiao, Yi Chai, Anthony Wamwea, Elaine O. Bigelow, Eric R. Lutz, Linda L. Liu et al. · 2014 · Journal of Immunotherapy
50. Programmed death ligand 1 signals in cancer cells
    Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler Jay Curiel · 2022 · Nature reviews. Cancer
51. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. Van Beijnum B, Patrycja M. Nowak-Sliwinska, Arjan W. Griffioen · 2021 · Nature Reviews Clinical Oncology
52. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
    Hallie Wimberly, Jason Robert Brown, Kurt Alex Schalper, Herbert Haack, Matthew R. Silver, Christian Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R. Lannin, David L. Rimm · 2014 · Cancer Immunology Research
53. Human papillomavirus as a driver of head and neck cancers
    Maria Elisa Sabatini, Susanna Chiocca · 2019 · British Journal of Cancer
54. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
    Curtis A. Clark, Harshita B. Gupta, Gangadhara R. Sareddy, Srilakshmi Pandeswara, Shunhua Lao, Bin Yuan, Justin Michael Drerup, Alvaro Souto Padron, Jose Ramon Conejo-Garcia, Kruthi Murthy et al. · 2016 · Cancer Research
55. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Liliang Xia, Yuanyong Liu, Ying Wang · 2019 · The Oncologist
56. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
    Anna C. Filley, Mario A. Henriquez, Mahua Dey · 2017 · Oncotarget
57. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy
    Jiao, Shiping, Subudhi, Sumit K., Aparicio, Ana, Ge, Zhongqi, Guan, Baoxiang, Miura, Yuji, Sharma, Padmanee · 2019 · Cell
58. Targeting the bone marrow microenvironment in multiple myeloma
    Yawara Kawano, Michele Moschetta, Salomon Manier, Siobhan V. Glavey, Güllü Görgün, Aldo Maria Roccaro, Kenneth Carl Anderson, Irene M. Ghobrial · 2014 · Immunological Reviews
59. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
    Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han · 2018 · Journal of Hematology & Oncology
60. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
    Dong Ha Kim, HyeongRyul Kim, Yun Jung Choi, Seon Ye Kim, Jung-Eun Lee, Ki Jung Sung, Young Hoon Sung, Chan‐Gi Pack, Minkyo Jung, Buhm Han et al. · 2019 · Experimental & Molecular Medicine
61. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions
    Wu, Ke, Kryczek, Ilona, Chen, Lieping, Zou, Weiping, Welling, Theodore H. · 2009 · Cancer Research
62. TLR signaling by tumor and immune cells: a double-edged sword
    Bo Huang, Jie Zhao, Jay C. Unkeless, Zhihui Feng, Huabao Xiong · 2008 · Oncogene
63. LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
    Feng Xu, Jing Liu, Di Liu, Biao Liu, Min Wang, Zhiyuan Hu, Xuemei Du, Tang Li, Fuchu He · 2014 · Cancer Research
64. PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
    Evan J. Lipson, Jeremy G. Vincent, Myriam Loyo, Luciane Tsukamoto Kagohara, Brandon S. Luber, Hao Wang, Haiying Xu, Suresh K. Nayar, Timothy S. Wang, David Sidransky et al. · 2013 · Cancer Immunology Research
65. Targeting PD-1/PD-L1 interactions for cancer immunotherapy
    Laurence Zitvogel, Guido Kroemer · 2012 · OncoImmunology
66. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
    Bellmunt, Joaquin, Powles, Thomas, Vogelzang, Nicholas J. · 2017 · Cancer Treatment Reviews
67. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma
    Orillion, Ashley, Hashimoto, Ayumi, Damayanti, Nur, Shen, Li, Adelaiye-Ogala, Remi, Arisa, Sreevani, Chintala, Sreenivasulu, Ordentlich, Peter, Kao, Chingai, Elzey, Bennett et al. · 2017 · Clinical Cancer Research
68. At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Andrew M. Intlekofer, Craig B. Thompson · 2013 · Journal of Leukocyte Biology
69. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
    Simon J. Dovedi, Eleanor J. Cheadle, Amy L. Popple, Edmund Poon, Michelle Morrow, Ross A. Stewart, Erik C. Yusko, Catherine Miller Sanders, Marissa Vignali, Ryan Emerson et al. · 2017 · Clinical Cancer Research
70. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
    Stanley J. Oiseth, Mohamed S. Aziz · 2017 · Journal of Cancer Metastasis and Treatment
71. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
    Anna E. Vilgelm, Ann J. Richmond · 2019 · Frontiers in Immunology
72. B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes
    Haidong Dong, Gefeng Zhu, Koji Tamada, Dallas B. Flies, Jan M. A. van Deursen, Lieping Chen · 2004 · Immunity
73. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
    Emilien J. Loeuillard, Jingchun Yang, EeeLN H. Buckarma, Juan Wang, Yuanhang Liu, Caitlin B. Conboy, Kevin D. Pavelko, Ying Li, Daniel R. O’Brien, Chen Wang et al. · 2020 · Journal of Clinical Investigation
74. Immunotherapy for glioblastoma: current state, challenges, and future perspectives
    Yang Liu, Zhou Fei, Heba A. Ali, Justin Durla Lathia, Peiwen Chen · 2024 · Cellular and Molecular Immunology
75. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    Offner, Sonja, Hofmeister, Robert, Romaniuk, Andrea, Kufer, Peter, Baeuerle, Patrick A. · 2006 · Molecular Immunology
76. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
    Janet Lau, Jeanne Cheung, Armando Navarro, Steve Lianoglou, Benjamin Haley, Klára Tótpál, Laura Sanders, Hartmut Koeppen, Patrick Caplazi, Jacqueline McBride et al. · 2017 · Nature Communications
77. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
78. Immunosuppression associated with chronic inflammation in the tumor microenvironment
    Dingzhi Wang, Raymond N. DuBois · 2015 · Carcinogenesis
79. Immunosuppressive mechanisms in glioblastoma: Fig. 1.
    Edjah Kweku-Ebura Nduom, Michael Weller, Amy B. Heimberger · 2015 · Neuro-Oncology
80. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
    Tessa Gargett, Wenbo Yu, Gianpietro Dotti, Eric S. Yvon, Susan N. Christo, John D. Hayball, Ian D. Lewis, Malcolm K. Brenner, Michael Paul Brown · 2016 · Molecular Therapy
81. Exploring immunotherapy in colorectal cancer
    Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang · 2022 · Journal of Hematology & Oncology
82. The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
    Brian T. Fife, Kristen E. Pauken · 2011 · Annals of the New York Academy of Sciences
83. Cancer Epigenetics, Tumor Immunity, and Immunotherapy
    Jian Cao, Qin Yan · 2020 · Trends in Cancer
84. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
    Chang Qing Yang, Bai-Rong Xia, Zhao-Cong Zhang, Yongjian Zhang, Ge Lou, Weilin Jin · 2020 · Frontiers in Immunology
85. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
    Jun Min Zhou, Kathleen Margaret Mahoney, Anita Giobbie‐Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott J. Rodig, Jingjing Li, Xinqi Wu, Lisa Helene Butterfield et al. · 2017 · Cancer Immunology Research
86. The interaction of innate immune and adaptive immune system
    Ruyuan Wang, Caini Lan, Kamel Benlagha, Niels Olsen Saraiva Câmara, Heather E. Miller, Masato Kubo, Steffen Heegaard, Pamela P. W. Lee, Lu Yang, Huamei Fu Forsman et al. · 2024 · MedComm
87. Prospects of RNA interference therapy for cancer
    Sara Isabel Pai, Y-Y Lin, Bruno Macaes, Avedis Meneshian, C-F Hung, T.‐C. Wu · 2005 · Gene Therapy
88. PD-L1 and Survival in Solid Tumors: A Meta-Analysis
    Pin Wu, Dang Wu, Li‐Jun Li, Ying Chai, Jian Huang · 2015 · PLoS ONE
89. At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
    Margaret K. Callahan, Jedd D. Wolchok · 2013 · Journal of Leukocyte Biology
90. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
    Zuqiang Liu, Roshni Ravindranathan, Paweł Kaliński, Zong Sheng Guo, David L. Bartlett · 2017 · Nature Communications
91. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi · 2016 · International Journal of Clinical Oncology
92. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
    Monica Marzagalli, Nancy D. Ebelt, Edwin Ramos Manuel · 2019 · Seminars in Cancer Biology
93. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Daniel Sanghoon Shin, Antoni Ribas · 2015 · Current Opinion in Immunology
94. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology & Therapeutics
95. Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
    Xavier Frigola, Brant Allen Inman, Christine Marie Lohse, Christopher J. Krco, John C. Cheville, Robert Houston Thompson, Bradley C. Leibovich, Michael L. Blute, Haidong Dong, Eugene D. Kwon · 2011 · Clinical Cancer Research
96. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
    Willem Joost Lesterhuis, Cornelis J.A. Punt, Stanleyson V. Hato, Dagmar Eleveld-Trancikova, Bas Jansen, Stefan Nierkens, Gerty Schreibelt, Annemiek J. de Boer, Carla M.L. van Herpen, Johannes H.A.M. Kaanders et al. · 2011 · Journal of Clinical Investigation
97. Twelve immunotherapy drugs that could cure cancers
    Martin A. Cheever · 2008 · Immunological Reviews
98. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
    Aaron Scott Mansfield, MC Aubry, Justin C. Moser, Susan M. Harrington, Roxana Stefania Dronca, S. S. Park, Haidong Dong · 2016 · Annals of Oncology
99. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
    Charlotte M. Roach, Nancy Zhang, Ellie Corigliano, Malinka Jansson, Grant Toland, Gary Ponto, Marisa P Dolled-Filhart, Kenneth Emancipator, Dave Stanforth, Karina Kulangara · 2016 · Applied immunohistochemistry & molecular morphology
100. Tumor infiltrating lymphocytes in ovarian cancer
     Phillip P. Santoiemma, Daniel J. Powell · 2015 · Cancer Biology & Therapy